OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD
OSE Immunotherapeutics Hosts KOL Webinar Post-ECCO on Lusvertikimab and the Future of IBD NANTES, France – March 6, 2025, 6:00pm CET - OSE Immunotherapeutics recently hosted a webinar featuring key opinion leaders (KOLs) to discuss the latest clinical …